The Cure: Revolutionizing the Business of Healthcare in Africa
The Cure is a deep-dive podcast exploring what it takes to revolutionize the business of healthcare in Africa. Hosted by Temitope Coker, each episode features candid conversations with the people shaping the continent’s health systems, including visionary founders, investors, researchers, policymakers, and reformers.
We go beyond surface-level insights to unpack the real-world challenges, innovations, and investment strategies transforming care delivery across Africa. At the same time, we aim to infuse hope into the narrative by spotlighting the momentum and progress already unfolding across the continent.
From financing and infrastructure to research, technology, and policy, The Cure is the place for serious thinkers and doers who care about the future of African health.
The show is powered by TC Health, a platform providing healthcare and pharmaceutical insights in Sub-Saharan Africa.
The Cure: Revolutionizing the Business of Healthcare in Africa
Paperwork to Platform: Reinventing Drug Regulation with AI- Part 1 | A Conversation With Irene Nwaukwa
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Paperwork to Platform: Reinventing Drug Regulation with AI
Before any drug reaches a patient, it has to pass through regulation.
But what happens when that system is slow, manual, and fragmented?
In this episode, Irene Nwaukwa, Founder & CEO of Infinity Health Africa, shares how regulatory bottlenecks delay access to medicine and how AI is helping change that.
If we want faster access to safe, effective drugs, this is the conversation we need.
🎧 Listen now
Hello, healthcare enthusiasts, and welcome back to The Cure. This is the podcast where we're revolutionizing the business of healthcare in Africa, one conversation at a time. I'm your host, Tim Tokwekoka, and in each episode, I sit down with the people that are shaping the future of healthcare in Africa. From founders to investors to policymakers and beyond. And our goal is very simple: to infuse hope back into the narrative by spotlighting the progress and momentum that's already unfolding across the continent. At the heart of every episode is one key question: What does it take to revolutionize the African healthcare business model? And all our insights are powered by TC Health, your trusted source for healthcare and pharmaceutical insights in Sub-Saharan Africa. So let's just get into today's episode. In season two, we're exploring what it takes to build the rails, you know, the regulation, the financing, the partnerships, the data, you know, the physical infrastructure that turns, you know, an idea to reliable care and sustainable care. And today we're going to talk about that one rail that every single medicine has to cross before it can legally even reach a patient. And it's the one almost nobody wants to talk about compliance and regulation. Here's a number that should bother every single person listening to this podcast. Africa has fewer than 400 drug manufacturers serving over a billion people. China, one country, you know, compared to Africa, one continent, has around 5,000 manufacturers. And India has more than 10,500. We import roughly 70 to 80%. That number is always varying of the medicines that we consume. And Nigeria alone spends over $2 billion a year bringing drugs in from outside the continent. The obvious response is to build local manufacturing. And Nigeria has a presidential initiative that's doing just that. And we'll get into that in a second. But there is a quieter bottleneck that's underneath everything. And before a drug can actually be made here, imported here, sold here, distributed here, it has to be registered. And registration in Nigeria can take anywhere from six months, 12 months, two years, four years.
SPEAKER_01Six months is six months is the most ambitious I've ever had. I don't think it's ever happened.
SPEAKER_05On paper.
SPEAKER_01Actually, six months is impossible. So the official number is 240 working days. Wow. Yes. To get a drug registered in Nigeria.
SPEAKER_05And our guest has decided that all of this paperwork, all of this delay was not a nuisance to be tolerated, but it was to build the rails, to build the infrastructure, and she set out to build it. So you've already heard her voice. Irene Nwalka is the founder and CEO of Infinity Health Africa, a regulatory technology and market access company that's working to improve access to innovative healthcare products across Africa. She spent more than 16 years on the commercial side of the pharmaceutical industry, launching and selling products across nearly every English and Portuguese-speaking market in Sub-Saharan Africa, potentially even Francophone, at companies such as Sanofi. And she describes herself as a reluctant entrepreneur. We'll get into that. One month before she started Infinity Health Africa, she was still telling people she would never run a business. And then her father needed a pacemaker that she could source in Kenya, where she was living at the time, but not in Nigeria. And not because it didn't exist, but because the manufacturer of that pacemaker could not navigate our regulatory environment in Nigeria. And that was the moment that the problem became personal. Since opening operations in April 2024, Infinity has managed over 200 product registrations and secured manufacturing facility permits and helped companies enter the Nigerian market. With services now running in Nigeria, Kenya, and Ghana, its platform Onboard started with a free product readiness calculator that has been used by more than 150 businesses. And earlier this year, in collaboration with the Presidential Initiative for Unlocking the Healthcare Value Chain, or PVAC, in collaboration with NAFDAC, in collaboration with the Pharmaceutical Manufacturers Group of Nigeria, and with the support of the World Bank Ecosystem and Google for startups, the team launched something genuinely new. It's called the Document Compliance Engine, and it's an AI-powered common technology technical document submission workspace that, in a pilot, it moved the first pass accuracy from under 50% up to almost 90%. And it cuts the queries in terms of regulatory queries by as much as 60%. Alongside building this company, Irene writes one of the sharpest blogs on African Health Systems. It's called At the Intersection, and you should all go and read, where she has made an argument that sits at the very center of our theme for this season. And we're going to spend some time on that today. But Irene, welcome to the cure.
SPEAKER_01Thank you. I mean, I was I was when you were doing it today. I was like, oh my God, this is a lot. How did I do all of these things? Um really what we were trying to do was, you know, try to solve underground problems that affect, you know, the things that people that the things that people see. There's a lot of things that happen in the background that affect access to care that people don't really know. Right. Um, for instance, one of the things, you know, when you're talking about common technical documents, most people outside of even in the pharmaceutical industry don't know what a common technical document is. Yeah. If you're not in regulatory, you don't know what a dossier is, which is you know the common balance for common technical documents. Um, and that dossier for pharmaceuticals is anything from a thousand from 600 to a thousand pages. Wow. You know, um, and regulators have to read it. Um, pharmaceutical companies have to present it for every single drug, every single SKU of every single drug, you know, that needs to come into the country. Um and these are the things, these are the underlying things that make these drugs available. You know, um these are some of the things that we we work on, you know. When you talk about things like readiness calculator, you know, some of the some of the things that we build, they're born out of, they're not born. In fact, when we started, we didn't know we did not even know that we're gonna do things like that. Yeah. We're born out of, you know, a place of sometimes pain. For instance, DC was born out of a place of um, we had a job to do. Yeah, it was a very hard job, and we kept asking the question what was the easiest, simplest way to go through you know these common technical documents. It were very voluminous, yeah, and very difficult to handle, and you know, we had a lot of customers to uh to manage at the time, and we were seeing a lot of um fraudulent practices in the in the space as well. We're seeing ways people were trying to circumvent you know those things, and regulators were using that, were saying, listen, because you know there can be errors in these places, we're going to make sure that we're we take exact care. Let me give you an example. NAFDAC insists that you see because they are backlogged, you know, they're short staffed. NAFDAC has about 3,000 staff. That 2,000 staff is very, very small number because if you give take, for example, you know, the FTA, 2,000 is like the staff strength of a department, not an entire agency, right? So now NAFTAC says, listen, we don't have enough staff to read through all of these documents, and you will keep submitting and submitting and submitting. So here's what we're going to do we're going to limit the number of times you can submit in a year.
SPEAKER_05I've heard this before. I was interning at a company and they were like, we can only submit like twice per quarter or once per quarter. And I was like, what?
SPEAKER_01And that number is it reduces every fact, every year it reduces, reduces, and reduces and reduces and reduces. So right now you can you probably can submit only maybe twice a year.
SPEAKER_05Wow. And where everyone wants local manufacturing, local manufacturing.
SPEAKER_01Local manufacturers, now there is a concession.
SPEAKER_05Okay, okay.
SPEAKER_01Local manufacturers can submit at any time.
SPEAKER_05Okay, okay. So international manufacturers are capped.
SPEAKER_01Yes. If you have a new drug, you can submit. They will give you a concession.
SPEAKER_05Okay.
SPEAKER_01But every other person in between can only submit twice a year. And it at a specific time when there's a specific window, there's a specific like there's a you understand, because of all of these things. Yeah. Because there's literally very minimal human capacity to do all of these things. So you know, when you when you're stuck in this kind of situation, you have to start thinking, yeah, how do we leverage the technology that's available? AI, you know, document management, you know, and all of the things that we see to break through and make these things available. Because tell me if your parent needs a drug and that drug is waiting to be registered, are you going to wait?
SPEAKER_05Are you going to go where the drug is registered? Yeah.
SPEAKER_01You know. So sometimes, and you know, I tell people one big thing people forget about compliance is this the rule of compliance is this. You need to make it first and foremost, it needs to be logically easier to comply than it is to not comply.
SPEAKER_04Yeah.
SPEAKER_01Then you can chase those who are not complying.
SPEAKER_04Yeah.
SPEAKER_01But in Nigeria, when systems are broken, what happens is that you know, it is logic, it is log it is illogical to comply.
SPEAKER_04Yeah.
SPEAKER_01So the people who comply, they look like fools, they feel punished. You know, the numbers don't look good on their tables. You know, the smugglers are making money.
SPEAKER_04Yeah.
SPEAKER_01And then the people who are complying are suffering.
SPEAKER_04Yeah.
SPEAKER_01So when we come into the system, we now have to, we go, you know, we I I learned something from um Abimbala when she says, you know, when you want to build something, go straight to the regulator. Went to the regulator and we said, listen, this is the problem you are facing. This is how we can build and solve, we can solve it. And we said, this is how we can solve this problem, and we can help everybody get it right.
SPEAKER_04Yeah.
SPEAKER_01Yeah. And we want to do it right. Our readiness calculator, you know how we built it? It started because people kept asking me, I just kept getting on calls that were not leading anywhere to say, what do I need to do to get my Navdark number? What do I need to do to get my Lavda number? So we built technology to help answer that question so that we don't have to spend the whole day on calls that are not really necessarily leading to sales, but are necessary, you know, that are that are good leads, yeah, but are not, you know, ne necessarily leading to sales, but are good for leads.
SPEAKER_05And it shows you, it it shows you where the gaps are. It also shows cons consumers or your potential customers, yes. Where they are falling short and would need help.
SPEAKER_01And you you know, one of the things you learn very quickly is this most companies do not know what they need to get it right with the regulator.
SPEAKER_05Yeah. Yeah. And I think that even beyond the requirements of the regulator, that is also a very valuable sales and marketing advice for our listeners because I read somewhere last week that the best way to gain trust with a potential customer is to actually tell them not to spend their money at first. Building this free readiness calculator is like, hey, don't spend any money. You don't have to pay us for a project. Why don't you check and see where you're at and where you stand? And that builds the trust to stay.
SPEAKER_01So, in you know, in compliance, one of the things that you don't even want to do is to collect money first. Because it's a trap. If you collect money from a customer who is not ready to go the long the full journey with you, you put yourself in a very bad position.
SPEAKER_04Yeah.
SPEAKER_01Because now you've collected money, you've contracted yourself to someone, and then they're not ready to finish. Yeah. They're not going to give you documentation, the right documentation. They're not going to so you can never close the sale. Yeah. You can never really complete the work. Yeah. You just have this thing hanging over your head for a very long time. You're never closing. You're never completing, you're never collecting your balance. You're never, you know, if you have some. Initially, we used to break our payments into two and say, okay, when we when we we have a success fee at the end. Yeah. I stopped it because customers maybe sometimes would give up at the somewhere at the end of it and we don't collect our balance.
SPEAKER_04Yeah.
SPEAKER_01So, you know, you're just punishing yourself for nothing. You know. So if you you you need to make sure that your customer understands the journey that they're about to embark on.
SPEAKER_04Yeah.
SPEAKER_01When we also came in, when we also started, we also saw that, you know, you know, this sector is very informal led. It's very consultant-driven. It's not a very product-driven sector. In fact, it was one of the biggest challenges to our fundraising because you see, when we said we're building Regtech, everybody said, ah, but is it not consulting? In fact, that's the first thing VCs will tell you. And I'm like, it's traditionally consulting, but we're building product out of it. We're reforming this sector. Yeah. And you know what it means is that where others were, you know, running it as a consultancy, where, you know, when people come and meet you, say, ah, you have Navdak agents, they have Navdach consultants, they want they run it a different way. They don't even tell you when you in fact, I I when we first started, some people charge you money to tell you what you need to what you need to do to what you need to know to get your Navdach number. Like what we offer for free. Yeah, they charge you money. They charge you money to teach you uh how to file, you know, things online, yeah, you know, and things like that. And you know, and I'm like an informed customer is beneficial to me. There's no reason to charge any money for that.
SPEAKER_04Yeah.
SPEAKER_01We want to build as many tools as possible that make it easy for you to comply. Yeah, it makes it it makes your journey with us one, it makes the conversion into the customer, into getting you as a customer easy for us. But also more importantly, it makes compliance for for you easy as well.
SPEAKER_04Yeah.
SPEAKER_01So we kind of like, you know, left and it differentiates us from you know everybody in the pack. So we we we let that out, you know, and we just started doing things, you know, significantly differently. We we realized very quickly that you know in this space, one of the ways we're gonna differentiate ourselves was you know with technology. Yeah. Because everybody was very traditional, everybody was, you know, doing things, you know, the traditional way, and one of the ways that we're going to do to to and especially you know when when we thought about you know specializing, you know, or really focusing on the pharmaceutical sector.
SPEAKER_00Yeah.
SPEAKER_01When you think about the pharmaceutical sector, how do I say it? It's very cabalized, sort of, you know, every it's sector is everybody knows everybody.
SPEAKER_04Yeah, yeah.
SPEAKER_01You know, so if we're trying to break in like that, you have to be you have to find you know that niche, what you're known for. So, you know, we looked at it and we said, you know, technology is what is going to set us apart, is what is going to help us, you know, come into this space. And really that's what's what's you know helped work for us.
SPEAKER_04Yeah.
SPEAKER_01Yeah. But if I tell you that we did not plan to start with regulatory, would you I know, I know.
SPEAKER_05When I did my stocking, I I saw that it was initially to provide healthcare data or data for healthcare companies, and then it evolved into specializing in you know the regulatory pharmaceutical industry.
SPEAKER_01So, like you said, I I I I did not plan to be an entrepreneur. I every time I look back, I I don't I I cannot imagine how I found myself here. Yeah, yeah. Um, because I I remember that, you know, when I was uh I I used to work at a startup, and I remember that shortly before that startup went closed down, this the founder had told me, you know, you could actually be a startup founder. It was the very first time anybody had ever said that to me. Um, and then some friends said to me, Irene, you know, you can actually do this. And they encouraged me. And I and now every time that I'm struggling with my setup, I tell them, naive people, you people convinced me that I could do this.
SPEAKER_05Yeah.
SPEAKER_01You know. Um.
SPEAKER_05But I mean, I'd like to take a step back. I want knowing the the richness of your experience, being in the pharmaceutical sector and working in regulatory and compliance now with the company that you're building. I want to paint a picture and set the stage for the listeners who want to understand what exactly are the signals that are shaping pharmaceutical regulation in Africa today. We already kind of started that conversation when we spoke about um on paper, it says six months for an accelerated, you know, um, reliance pathway to get a drug approved in Nigeria. But in reality, it's it's much, much longer. And, you know, we tend to talk about regulation the way we talk about traffic. Like it's something that slows you down, it's something that delays you, it's something that you have to work your way around. But like everything you've just said, regulation is one of the most essential infrastructure. Infrastructure doesn't have to be physical, but your regulator is part of the infrastructure of the market. And like you said, it's the difference between a generic that controls your mother's blood pressure and one that is actually not doing anything when she believes that she's being treated. And the scale of the problem. Is not some abstract problem because we've seen studies from the WHO that estimate one in 10 medical products in low and middle income countries is substandard or falsified. Even a 2024 systematic review of Africa put that figure at roughly one in five. And then in Nigeria, in that paper, it sat at the worst end of that range with studies saying it can be as high as 75% in some samples. And so I think when you see this sort of dynamic, we start to understand the real challenges that are facing the regulatory landscape. And so much of that friction has so many costs. And one of the costs, like we've discussed, is time. Okay, only the regulatory regulators review time, but they don't measure the queue before review begins. They don't measure the time, the months an applicant will spend answering queries back and forth on the application. On paper, like we said, on paper, Nigeria targets around 240 days for a full review. Ghana is averaging about 56 days on paper. They're leaning on reliance pathways. But there's a widely cited review of medicines regulation in Sub-Saharan Africa, and it found a typical lag of potentially up to four years and sometimes up to seven years between when a company first submits to a national regulator and when they get their final approvals, and you can actually sell, market this product.
SPEAKER_01So I'll tell you this. I've been in the pharmaceutical industry for the last 18 years now. Um I've launched products in a lot of African countries. Um on the average, it will take you to two and a half years if you were if you're slow three years to get a product from when you submit to when you get your product in in country. Yeah. Right. Um get your permit and you get your product in country and selling. Yeah. That's what it will take you. If you if you it really that's a realistic timeline. Um it's it's crazy. It is. Now there are real reliance pathways that you can use, um but those are limited to very specific products, right? Um and they are really limited to products that are to products that are novell in nature.
SPEAKER_05Yeah as well. Can you define for our listeners what a reliance pathway is?
SPEAKER_01So reliance pathway is let me use let me use um a let me use this HIV drug as an example. So you know Lena Kapavir. Yeah. The the new HIV drug that you take twice a year.
SPEAKER_04Yeah.
SPEAKER_01That you know you can take twice a year to prevent HIV, right? Um it was approved in the US by the FDA, right? Now, the FDA has gone through, they've gone through the rigorous review by the FDA.
SPEAKER_04Yeah.
SPEAKER_01When they come when they came to Nigeria, it's now registered in Nigeria.
SPEAKER_04Yeah.
SPEAKER_01When they came to Nigeria, instead of going through the rigorous, that rigorous review in Nigeria, they went through a reliance pathway, meaning that they submitted what they submitted to the FDA in Nigeria. Yeah. Nigeria reviewed what the FDA reviewed and said, okay, we trust what the FDA has reviewed of these guys, yeah, and we approve based on what the FDA has approved. That's a real that's a reliance pathway.
SPEAKER_05It sounds like it's gonna sound so silly. You know, when there's certain countries that if you have a US visa or Schengen visa, exactly you can enter the country because they're like there's no amount of rigor we can do that's beyond what the US or Schengen area has put you through for your visa.
SPEAKER_01Exactly. So they will they will basically just what they would now do is verify that what's that what that your US uh permits is actually legit. Yeah. Right. And then they will give you a they will give you a permit on the basis of your US you know approval. Yeah. That's the reliance pathway.
SPEAKER_05Yeah. And these delays, I mean, the one thing.
SPEAKER_01Well again, it is limited. It is very limited. It's not everybody that can do a reliance pathway.
SPEAKER_05And I think it's you know, when I think about it, almost every c country on the continent and the continent itself has goals to improve the proportion of local manufacturing, like the proportion of locally manufactured drugs that are being consumed on the continent. However, when you're faced with, let's use a local Nigerian pharma company A, wants, has their own anti-malarial. But it's their own anti-malarial in their portfolio, and they want to submit, and it takes two and a half years to get approval by NAFDAC. But let's say Novartis, let's say Roche, let's say GSK, all these big global pharmaceutical manufacturers can get their drug approved six months, 12 months in the FDA.
SPEAKER_02It's not possible.
SPEAKER_05And then get a reliance pathway, and you're in the market quicker. It's not possible.
SPEAKER_01So that's that's the thing. It's not it's that's not that's not how it works. The reliance pathway is limited to certain medications, right? And they have to be, like I said, they can't, they're they're quite novel in nature. Um, so and then Nigeria also has what is called the five plus five list. Nigeria has what is called the ceiling list. Nigeria has what's called the import prohibition list. These three lists are very important.
SPEAKER_04Okay.
SPEAKER_01The five plus five list is um the five plus five policy has been a policy that has been in place for a very long time now, but is now under very strict enforcement. Five plus five basically means this. If you're a multinational or you're an importer, you bring in, you've been bringing, you're bringing in a product into the country, right? The first five years, they give you your for pharmaceutical products, your permit lasts five years, right? For certain products, after the first five years, you have to start that first five years, you're going to use it to start engaging with local manufacturers for technology transfer because the next the next one, your next renewal, after your next renewal, you will not be allowed to approve to to um renew anymore.
SPEAKER_05Okay.
SPEAKER_01You would have to produce locally, that product will not be allowed to be imported anymore. So for instance, okay, there are many penicillins. Right now, if you notice, there's a lot of antibiotics that are produced locally that are no longer being imported. It is because of five plus five lease. So there are some anti malarials that are no longer being imported. It is because of the five plus five lease.
SPEAKER_05So five plus five, an international manufacturer has that initial five-year permit, and they have to do something to transfer that technology locally because the next five years they won't get that unless they've transferred locally. Interest. I love that. Okay, okay. And then you said there's other two lists as well.
SPEAKER_01Oh yeah. Now then there's the ceiling list. The ceiling list is then there's a ceiling list, is NAFTAC ceiling list, meaning that this these lists, this that ceiling list is a list of products that are not allowed to be imported locally.
SPEAKER_04Okay.
SPEAKER_01So these are products that must only be that must only be produced locally.
SPEAKER_05And what kind of products are on that list?
SPEAKER_01The whole number of products. Um a lot of your albendazoles, a lot of all your vitamin Cs and coal, all your parasitamols, all your can I remember now most of what is on that list?
SPEAKER_05They cannot be but these are your commonly used.
SPEAKER_01Yes, a lot of essential medicines cannot be right. So then you have your import prohibition list from customs from the federal government. Um, and so all of these three lists make up a list that ensure that your local manufacturing your local manufacturers are to a large extent protected, exactly. Okay. The goal is that to a large extent more and more of our essential medicines are being produced locally, and we're encouraging you know our local manufacturers to produce locally while you know um while the rest can now be imported.
SPEAKER_04Yeah, yeah.
SPEAKER_01Now you mentioned something about substandard medicines. The thing about substandard medicines is this bad actors always try to fly under the reader, right? You would hardly find a medicine that has gone through NAFTAC rigor that is substandard. But you will find, but you know, these are the guys who are either falsifying, you know, adult counterfeiting and already approved medicine, yeah, or they are smuggling counterfeit medicines, yeah. And they are existing because maybe bother that porous, you know, things are yeah, and supposed to be a lot of things are happening right now that are trying to solve those things. For instance, with the single trade window, things are getting tighter. For instance, with single trade window now, it is very hard for you to smuggle medicines.
SPEAKER_05Explain what the single trade window is.
SPEAKER_01So single trade window is a new policy that came in that was recent that was implemented this year.
SPEAKER_04Okay.
SPEAKER_01Right. Without it, you cannot without with a single trade window, all your NAFTA um all your NAFTAC um all your uh pharmaceutical imports are under your account. You cannot use different accounts to import your pharmaceutical products.
SPEAKER_04Okay.
SPEAKER_01So now customs can look and trace it's everything goes through one account. Yeah. Customs is now checking is direct from Navdach. Yeah, is this product approved? If they don't see your NavDAC permits, your product is ceased at the port.
SPEAKER_05Yeah.
SPEAKER_01At any port.
SPEAKER_05Yeah. And I love that I love when guests challenge widely held assumptions because the theme of our podcast is to infuse hope. Like our goal is to infuse hope. And I think people are so used to, uh, are you sure this drug used in Nigeria is safe? If it's a Nigerian-made product, are you sure it's safe? But your what you've just described over the past five, 10 minutes is several, it's like a whole customized package of policies that are not only aiming to protect our local industry, our local pharmaceutical industry, but to ensure that the products for Nigerian patients are safe. And so if you hadn't challenged those, you know, widely held assumptions. If you talk to the average Nigerian on the street, they will believe that. They were like, oh, yes, nobody's doing anything, right?
SPEAKER_01We if you know, we we've always lived with the fact that, oh, you know how they say we like we want the UK one. Let me I always tell people something. Nowadays I'm very cautious about you know people who go to go abroad, take a pack of drugs abroad, put a pack in a bag, and start coming to Nigeria.
SPEAKER_04Yeah.
SPEAKER_01And you know, they think they are getting good drugs. You know, people forget that drugs are made for a specific region.
SPEAKER_04Yeah.
SPEAKER_01There is what is called stability for a region. Yeah. Now, well we are in you know what is called WHO climatic zone 4B, meaning that, you know. It's hot. Exactly. It's hot. Room temperature here is 30 degrees. Yeah. Right? It gets to 35 degrees here. You went and carried a drug that is stable at 25 degrees and came here where they have packed it inside, I don't know where. And you think that you're you and you're yes and you're comfortable.
SPEAKER_05Yeah. That's actually a fantastic point, honestly. And a mentor of mine even in um mentioned a point around, you know, you have the WHO regular regulatory review, WHO pre-qualification. WHO pre-qualification, obviously, they will go through the GPU. Yeah, your good manufacturing practice, your GMP, et cetera. But there's hardly checks of the product that has entered into the African market. So you've checked that, okay, their facilities are great at the time of that assessment, et cetera. But when sometimes you'll find, especially from you know, certain regions like India, like China, when those drug products are then imported at the point of import, at the point of entry into the African market, who is checking that the product that reaches our market is also aligned with what was, you know, pre-qualified or that the standard has remained the same. So again, there's all these dynamics of why do we trust others over ourselves?
SPEAKER_01So on WHO prequalification for manufacturing, there is that that's a different, you know, kettle of fish on its own. So for GMP for manufacturing is a standard for you know certain drugs that are donated for most people. This is the reason why most people like to talk about the precue. Donors buy based on WHPQ. Right. Um, good transportation practice, good you know, storage practice, good distribution practice, all of those things are also necessary. Yeah. Right. To make sure that when you when you're just when you're when you buy those drugs from wherever, you know, you're trying you when you're bringing them here, they're within the same, with the right temperature, the right, you know, um humidity, in the same, you understand? Yeah. In the right packaging, the same in the right um conditions, right? Um, storage conditions and all of that. That one is those ones are never really, and NAVDAC always checks, you know, at the pot. So they always check at the pot. So those ones are not, those are not us really the problems. The problem is usually is always with the smugglers. And you know, most people don't think that they are smugglers, but they are because you know, let me tell you, do you know the definition of a fake drug according to NAFTAC?
SPEAKER_05I'd love you to explain.
SPEAKER_01Definitely a fake drug according to NAFTAC is a drug that has not been assessed by NAFTAC.
SPEAKER_05That's it. So the people going to booths in London and packing ibuprofen in their suitcase and coming into Lagos useful as she might be classified as a smuggler. That's but that's what they're doing.
SPEAKER_01That's the smuggling. That's so what is it? Oh god no, what is it? Yeah, it's got for me, you're a smuggler. You know, um the Network is trying to stop these things because one, you're bringing in drugs that are not at the right, you know, storage conditions for our region.
SPEAKER_03Yeah.
SPEAKER_01They're not, you know, if you want to, if you want to bring in, if you want these drugs, then there's a pathway for registration for this drug.
SPEAKER_03Yeah.
SPEAKER_01Then go through the right pathway for registration for these drugs. Bring them in through the right pathway so that we know that you're taking responsibility for these drugs, yeah, and then have them in the country.
SPEAKER_03Yeah.
SPEAKER_01Right. But we're not doing that. Now, the other thing that is happening is we're seeing less and less of the bigger multinationals from our shelves. Just to go back to you know, your question on the bigger companies, yeah. We're seeing less and less of the multinationals on our shelves.
SPEAKER_02Yeah.
SPEAKER_01Um, and what has happened is you know, some part of it is five plus five. Yeah. Because, you know, a lot of them, well that that time is up. Right. For some others, the it is that the markets is not very favorable for them right now.
SPEAKER_04Yeah.
SPEAKER_01Right. So a lot of multinationals have either exited or have reduced their operations in our markets. Yeah. Now, what we're seeing a lot more of our regional players like Indian, Chinese, a lot of the Asian guys. But we're also seeing more and more of local manufacturers on our shelves with more and more, you know, of their of their brands as well.
SPEAKER_04Yeah.
SPEAKER_01Right. Um, and more and local manufacturers are expanding. What is being produced, what their capacity for production in Nigeria is expanding. There are more beta lacter manufacturing facilities opening up in Nigeria today.
SPEAKER_04Yeah.
SPEAKER_01This thing used to be so from two, three years ago.
SPEAKER_04Yeah.
SPEAKER_01You know. So these are things that are are as a result of the policies that are being enforced currently. Yeah. You know, there are also more policies like the you know VAT exemption upon for pharmaceuticals, you know. And APIs, and yeah, we can favoring, you know, local manufacturers. That also have led to slight a slight you know reduction in cost of medicines, you know, and so these are the things that help you know um local manufacturers. Yeah. So a lot of concessions, a lot of concessions are really being given. Both from the regulation, like I told you, right now if you are a foreign if you are an importer, you have to wait for whenever the window is open. Yeah. For you to be able to register your products. Except you have a Novel drug, you know. Let's say that you know you want to register a I don't know a new drug like like that um Lena Kapavir now. Yeah, yeah. Right. But I thought you know the thing, like in Novel Drug, you're registering. If if not, if you don't have any new drugs to register, you have to wait for whenever the window opens so you to register a drug. But if you're a local manufacturer, all you need to do is just go to the nav talk and say, I want to register my drug.
SPEAKER_00You can't register your drug. Yeah, yeah.
SPEAKER_01You know, you have free access, you know, you have better open, you have you have a lot more, you know, easier. You have not really the rules are not really more relaxed, yeah, but you have more access, you know, simply because they're trying to spur, you know, um, a lot more growth within the local manufacturing industry.
SPEAKER_05Yeah. Yeah. Yeah. And just based on this kind of trend of more favorable policies, we're also seeing that uh so many regulators on the continent are advancing. So, for example, NAFDAC reached WHO maturity level three a few years ago. That's kind of the standard the WHO uses to certify a stable, well-functioning regulatory system. And we have nine African countries that are at maturity level three. We have Egypt, Ghana, Nigeria, Rwanda, Senegal, South Africa, Tanzania, Zimbabwe, and most recently Ethiopia, which attained it in October 2025. I'm also eyeing Kenya very closely because I think Kenya is coming up very soon. But we also have the African Medicines Agency now being, you know, live and fully operational. They've um we have 29 African Union member states that have ratified the treaty, i.e., they are aligned to whatever the AMA is doing. And we now have our first director general, the former head of Ghana's FDA, Dr. Delacy Mimidako. And even this past week, the US FDA and the African Medicines Agency, the AMA, formalized this landmark partnership. They signed a statement of cooperation to strengthen that regulatory harmonization, information sharing, clinical oversight, you know, access to these quality assured medicines across Africa. So we're seeing so many, you know, not just Nigeria level policies, but we're seeing continent-wide policies. And lastly, just to zoom in on a Nigeria-level policy before we go into you as the reluctant entrepreneur, um, on the industrial side, the presidential initiative for unlocking the healthcare value chain PVAC is actually one of the most innovative and forward-thinking policies I've seen in a very long time. It was launched in October 2023 under the current administration. And one of its targets is local production of 70% of Nigeria's health products by 2030 and to double the country's share of the African pharmaceutical market to at least 15%. I.e., Nigeria represents at least 15% of the African pharmaceutical market. I know you have worked very closely with PIVAC for your DCE product, and we'll jump into that. But I just wanted to get your thoughts on not just the Nigerian-level policies, but also the continent-wide policies and how that is creating the landscape that is primed for Infinity Health Africa being in this space right now.
SPEAKER_01So it's when you were talking about um Nigeria, you know, um NAFTAC becoming um um uh um ML3. NAVAC is not just an ML3 um regulator. So NAFTAC became an ML3 regulator some two, three years ago. They retained it.
SPEAKER_04Yeah.
SPEAKER_01Yeah. Last year they got inducted into the International Council of Harmonization, um, ICH, which means that not only are they, you know, seen as a stable regulator, they are also now in the council that sets the rules. Right. Um they also what this also means, and then they're now going for, you know, ML4, what is called SRA, stringent regulatory agency. What that means, you know, is that if NAFTAC well where they're going for is such that if NAFTAC, you know, approves a product, you can now they can you can do you can use a reliance pathway. You know, like a US will say, okay, we can rely on that's a NAFTAC approval. Yes.
SPEAKER_05That's like if we go back to the visa analogy, that's like your Nigerian passport. Yes, you can just enter the US or Europe. But you see, that level.
SPEAKER_01But yeah, that's game changing. But you know, like I always say, it has to go hand in hand with the market. So when Navdak achieved ML3, and it was a great thing, you know, but if you think about it this way, if you're if you are teaching in a school, right, and you attain a professorship and your students are still at primary school level, you know. I love that. You you kind of have not really gone far very far. Yeah, you're still gonna be very frustrated.
SPEAKER_04Yeah.
SPEAKER_01So we still need to, you know, and this is where why Infinity Health is where we is is doing what we're doing. Our work centers on bringing, making sure that, you know, as the regulator is going for reaching for the stars, we are making sure that the market can meet up. Yeah, you know, is we're innovating and making sure that compliance is easy and simple for the market as quickly as possible, as well.
SPEAKER_04Yeah.
SPEAKER_01Because usually, normally, you know, it should be the other way around. It should be that the market is innovating faster than the regulator can catch up.
SPEAKER_04Yeah.
SPEAKER_01But right now, the regulator is the regulator, the regulator seems to be moving, you know, faster than the ahead ahead from the markets. And it's just historical, you know, from the pharmaceutical, from for healthcare in general, because of how you know tightly regulated healthcare historically has been, you know, and the pharmaceutical industry, and how backward our pharmaceutical industry, you know, has been. So what we're trying to do is push you know this forward, right? Um so many countries. The one of the one one good thing that is happening as well is with all that is happening, there's been a lot of talk about harmonization, harmonization, harmonization. I'm really hopeful that they will round up like all of this harmonization will actually lead to the actual operationalization of this harmonization.
SPEAKER_04Yeah.
SPEAKER_01Right. Because one good thing about pharmaceuticals is this, you know, one of the reasons why we're able to build DCE and we're able to why DCE is very scalable, is because common technical documents are global. Yeah. It's one CTD. Can you explain what the CTD is? So the CTD, the common technical document, is there is a global way to do a common technical document. It is the same in Nigeria, it is the same in Brazil, it is the same in Angola, it is the same in Comoros. So, you know, there is only one, it's made of five modules. That's you know, 600 or 300 to 1,000 page document, you know, has only it has five, it's made of five modules, right? It's only module one, which is not really technically a part of a part of the C C D that is different from country to country. Okay, right. So it's called module one is called the regional summary. That is the part that is different from country to country. Yeah, module two to five is the same everywhere in the world, right? Now, the way the world is going is one global C T D. Yeah. Such that if a drug is approved in Nigeria, it can go anywhere, it can be used anywhere. Right? That document can be is valid everywhere because of the complexity of the document. Now, harmonization for Africa would mean if a drug is approved in Nigeria, don't have to carry that my 1000 page document again to Kenya, don't have to carry my 1000 page document again to Ethiopia. Because you know, it is two years in here, two years here, two years here, two years here.
SPEAKER_00Yeah, it's crazy.
SPEAKER_01Yeah, you know. So we need to make sure that drugs can get to patients on time because it's well when we say when we when we're saying two years here, two years here, yes, rigor is important and all, but it's two years of people not getting the drugs that they need. And you know, let me tell you something very important. You know that from I once did an article that you know from when it from when a drug is developed to when it gets to patients, to when it gets to the African patient, it takes about 50 years.
SPEAKER_04Wow.
SPEAKER_01Yes, most of the drugs that we commonly use today that are ever our steep everyday staple, they're about 50-60 years old. Augmenting is about 50 years old.
SPEAKER_05Yeah, that's a lifetime Osama. Yes, yeah.
SPEAKER_01Drugs do not get to us on time, yeah.
SPEAKER_05And also when you think about the life expectancy of the average African, I think we're close to 60, maybe going on close to between 60 and 70, maybe high low 60s. So that is close to a lifetime.
SPEAKER_01Nigeria, life expectancy in Nigeria is 54.
SPEAKER_05Exactly. So it's somebody's lifetime that is taking a drug to get the person cannot wait. Like no one can have.
SPEAKER_01Most of the drugs that we use locally that are our common everyday drugs are 50, 40, 50, 60 years old.
SPEAKER_04Yeah.
SPEAKER_01Most of the newly developed drugs do not get to us.
SPEAKER_04Yeah.
SPEAKER_01Wow.
SPEAKER_05Wow. And we're not studied enough. I want to be studied. Listen, that's a whole different ballgame. You know? Yeah, yeah. Wow. Very multifaceted challenge. Yeah. Yeah. So I want to understand how you got into Infinity Health Africa. I I know the story that you told when I did my stalking of you of your father needing a pacemaker in, I think it was 2020.
SPEAKER_03Yeah.
SPEAKER_05And how you could, you were living in Kenya at the time. You could get one in Kenya, but you couldn't get one in Nigeria where your father was. And the reason was regulatory. And I would love for you to walk us through that. And when did you realize that that journey to then what Infinity Health Africa does?
SPEAKER_01So that journey was not what made me do regulatory, but that was what made me know that I was going to do regulatory. It was it was to me, it was a bit of a it was a bit of a confirmation for me. So um when I was in Kenya, um my dad needed a pacemaker. Um and it was at the height of COVID.
SPEAKER_04Yeah.
SPEAKER_01And we're looking for this pacemaker everywhere in Nigeria. We couldn't, and and I and I had it easily in Kenya. We later found pacemaker. Um we're looking at double chamber, but we later found a single chamber pacemaker. And I remember every time that we subsequently, every time we would we would go for you know checkups with him, and you know, the the uh the cardiologist would say, Oh, why didn't you get you know this other high-tech? And I would just be so annoyed, and I'd just be like, please, don't even annoy me. If you know if you know how hard it was for us, we won't get this one we saw. You know, and then years later, when and outside of Infinity Health, you know, the company who that that makes the pacemaker had come to us saying Wow, full circle. Yeah, we had we having regulatory issues, you know, with with bringing in this pacemaker, um, and these were the issues, and that's why we always have we we never really have a lot of stock in the country and all of that. And so, you know, for me, that made me realize, okay, this is why I'm going to focus and stay here. But that was not what what why we why we did it. We did it because, like I said, when we started, um, I wanted to provide data for healthcare businesses because um I was just out of a health tech company, I was just out of working for a health tech company that just folded, and I wanted to help healthcare businesses.
SPEAKER_04Yeah.
SPEAKER_01I have one major thesis about healthcare businesses. I believe that you know, if we're going to have health care, good healthcare in Africa, that we cannot keep having pockets of excellence, that we have to have widespread excellence. So, you know, every all the mom and pop, you know, healthcare centers have to survive, thrive. Yeah, and most people who are starting up healthcare businesses don't have data.
SPEAKER_04Yeah.
SPEAKER_01What happens is that you know, a lot of the health the data in healthcare is very informal. And so what happens is that you go, you invest, and then when you when you start, you start to see surprises. Yeah. Um, and I always used to give, you know, this example that you know today if you wanted to know how many people have died of diabetes-related complications in a particular area, where would you get that data? Right? How many how many appendices is I in code? Yeah, you should know everybody has one, and you know, several people like if if somebody if you have if you know that a certain section of these people have had appendicitis and have had an appendix, their appendix removed, you should know that you know this is the number of people, estimated population of people with an appendix in this look local. Yeah, in developed countries, then this information exists, yeah. Right. So we set out to, you know, to find out. Um, but then we realized that you know we needed to raise money, um, a lot of money to be able to do this, and this is not something I'm very good at. I'm still not very good at raising money. Um, we need to raise money. I'm not very good at raising money, so I but I'm very I'm very good at you know talking to the markets, yeah, you know, engaging with customers. And every time people kept telling me, you know, I you've been in the in health in the healthcare market for a very long time. How do you solve this regulatory problem or the other? And so I decided to, you know, answer the regulatory problems as they were coming. Yeah, yeah. And it was a real problem, you know. I remember I think it was Health Tracker was our first customer that came to us, you know, to solve a problem. And so we got on it. And just like that, we started. I have the I I had a policy then that you know I don't start anything with like I don't I use customer money to register the company. Like I don't use my money to register the I use because I use I validate my willingness with the willingness to pay based on what's the customer is paying.
SPEAKER_04Yeah.
SPEAKER_01So we got our first set of customers, registered the company and started out.
SPEAKER_04Yeah.
SPEAKER_01And then, you know, and I remember taking our first deck to NAFTAC and talking to the guys at NAFTAC. Then, like, huh? In three months, the guy looked at me and said, You promised somebody that you will deliver what in three months? I'm not with you. I mean, who did you promise this? Please remove this. We don't promise permits in any in any amount of that. We promise a decision. Yeah, that decision may or may not be a permit. So, you know, if you notice all this time, I I I tell you, you know, I always give an estimate and I don't do, I also don't promise timelines. Yeah. Because you cannot promise a timeline and be a public regulator. It is one of the easiest problems to get into. In fact, one of the first problems you will get into. You know, and then when we first started, people will, the first question everybody kept asking us is, what do I need to do to get my NAFDAC perimeter? So that's why we built our, you know, the readiness calculator. Because we kept on we're spending so much time in meetings with people explaining documents that they needed. So we built, you know, a GPS of sorts, right? That helped them understand what documents they need to get their NAFTAC, you know, to get their NAFTAC permits. Then we got while we're doing that, we got started engaging with the pharmaceutical industry.
SPEAKER_04Yeah.
SPEAKER_01And then we got some customers, and then they we were handling a lot of documents and it was getting overwhelming.
SPEAKER_00And I remember you know, sitting with my team and asking, What is the easiest, simplest way to deal with this thing?
SPEAKER_01You know, and remember waiting for window. I remember the first time I dealt with the window, with having to deal with waiting for the window to open. Let me tell you, the first time I have to deal with deal with the window, they're waiting for you know the window for application for pharmaceutical applications. So we're waiting for the window to open. The window opened at midnight. Yes. They had the window was going to open at midnight. They were going to take the first 300 applications, and then the window was going to close. We were part of those that group. Those 300 applications were done exactly 90 minutes later.
SPEAKER_07Yeah.
SPEAKER_05So by 1 30 a.m., 300 regulatory representatives of multiple pharma companies or had applied by 1.30 a.m.
SPEAKER_01Yeah.
SPEAKER_05That's the shear volume of demand.
SPEAKER_01It was done. Wow. It was one of the craziest things. My client was with me on, I told her to stay online so that she can see. So it's not as if, you know, it's like she was shocked.
SPEAKER_05And let's do the math. 300 applications in that window. You said each one can be thousands of pages. Yes. And NAFDAC only has 2,000 staff.
SPEAKER_01Yeah. Which ordinarily are not the ones reading reviewing. Maybe it's both people that are reviewing are maybe like.
SPEAKER_05Our conversation with Irene Mwauka, the CEO and founder of Infinity Health Africa, was so rich and insightful that we had to split it into two episodes. So stay tuned for part two, where we deep dive into all things about the regulatory landscape in Nigeria and Africa as a whole and the amazing work she's doing in the regulatory tech space with Infinity Health Africa. Don't forget to subscribe to The Cure wherever you get your podcast and across all social media platforms at TheCurePod Africa. And we'll see you in the next episode. Bye.